Enrollment Complete for Trial of Therapy for Leber’s Hereditary Optic Neuropathy
GenSight Biologics has completed enrolling patients in its Phase 3 REVERSE clinical trial evaluating GS010 as a treatment for Leber’s Hereditary Optic Neuropathy (LHON). LHON is a rare inherited mitochondrial disease that is passed on by the mother. It causes degeneration of retinal cells in an offspring, leading to…